RU95101728A - Preparation exhibiting immunomodulating properties - Google Patents

Preparation exhibiting immunomodulating properties

Info

Publication number
RU95101728A
RU95101728A RU95101728/14A RU95101728A RU95101728A RU 95101728 A RU95101728 A RU 95101728A RU 95101728/14 A RU95101728/14 A RU 95101728/14A RU 95101728 A RU95101728 A RU 95101728A RU 95101728 A RU95101728 A RU 95101728A
Authority
RU
Russia
Prior art keywords
hybrid protein
buffer system
salt buffer
preparation
protein
Prior art date
Application number
RU95101728/14A
Other languages
Russian (ru)
Other versions
RU2102988C1 (en
Inventor
Е.В. Зинченко
А.Н. Панин
В.Б. Зинченко
В.А. Шмелев
В.М. Колышкин
Original Assignee
Е.В. Зинченко
А.Н. Панин
В.Б. Зинченко
В.А. Шмелев
В.М. Колышкин
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Е.В. Зинченко, А.Н. Панин, В.Б. Зинченко, В.А. Шмелев, В.М. Колышкин filed Critical Е.В. Зинченко
Priority to RU95101728A priority Critical patent/RU2102988C1/en
Publication of RU95101728A publication Critical patent/RU95101728A/en
Application granted granted Critical
Publication of RU2102988C1 publication Critical patent/RU2102988C1/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

FIELD: biotechnology, veterinary science, pharmacy. SUBSTANCE: invention proposes preparation exhibiting immunomodulating properties and containing hybrid protein T-FNO-T isolated from microorganism with the inserted recombinant plasmid pThi 325 encoding synthesis of protein, stabilizing additions and salt buffer system at the following ratio of components, wt.-%: hybrid protein 0.0008-0.0015; stabilizing additions 10-20; salt buffer system at pH = 7.0-7.2, and water - the rest. Stabilizing additions: polyglucin, gelatinol, sucrose; salt buffer system - buffered saline solution of sodium chloride. Lyophilized medicinal preparation can be used for nonspecific prophylaxis and treatment of infectious diseases. EFFECT: high purity of preparation, absence of by-side effects. 6 tbl

Claims (1)

Изобретение относится к биотехнологии и ветеринарии, а именно к получению лиофилизированных лекарственных форм, обладающих иммуномодулирующей активностью и может быть использовано для неспецифической профилактики и лечения инфекционных заболеваний. Задача изобретения - разработка лекарственной формы высокоочищенного иммунобиологически активного препарата на основе гибридного белка Т-ФНО-Т, не имеющего побочных токсических эффектов. Поставленная задача решается тем, что предложен препарат с иммуномодулирующими свойствами, содержащий гибридный белок Т-ФНО-Т, выделенный из микроорганизма, в который введена рекомбинантная плазмида pThy 325, кодирующая синтез белка, стабилизирующие добавки и солевая буферная система при следующем соотношении компонентов, мас.%: гибридный белок 0,0008 - 0,0015, стабилизирующие добавки 10 - 20, солевая буферная система pH 7,0 - 7,2 1,03 - 1,06, вода остальное. В качестве стабилизирующих добавок используют полиглюкин, желатиноль, сахарозу, в качестве солевой буферной системы - забуференный физиологический раствор хлорида натрия.The invention relates to biotechnology and veterinary medicine, in particular to the production of lyophilized dosage forms having immunomodulatory activity and can be used for non-specific prophylaxis and treatment of infectious diseases. The objective of the invention is the development of the dosage form of a highly purified immunobiologically active drug based on the hybrid protein T-TNF-T, which does not have toxic side effects. The problem is solved by the fact that the proposed drug with immunomodulating properties, containing a hybrid protein T-TNF-T isolated from a microorganism, into which a recombinant plasmid pThy 325 encoding protein synthesis, stabilizing additives and salt buffering system was introduced in the following ratio of components, wt. %: hybrid protein 0.0008 - 0.0015, stabilizing additives 10 - 20, salt buffering system pH 7.0 - 7.2 1.03 - 1.06, water the rest. Polyglucin, gelatin, sucrose are used as stabilizing additives, and a buffered physiological solution of sodium chloride is used as a salt buffer system.
RU95101728A 1995-02-10 1995-02-10 Preparation showing immunomodulating activity RU2102988C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU95101728A RU2102988C1 (en) 1995-02-10 1995-02-10 Preparation showing immunomodulating activity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU95101728A RU2102988C1 (en) 1995-02-10 1995-02-10 Preparation showing immunomodulating activity

Publications (2)

Publication Number Publication Date
RU95101728A true RU95101728A (en) 1997-02-27
RU2102988C1 RU2102988C1 (en) 1998-01-27

Family

ID=20164606

Family Applications (1)

Application Number Title Priority Date Filing Date
RU95101728A RU2102988C1 (en) 1995-02-10 1995-02-10 Preparation showing immunomodulating activity

Country Status (1)

Country Link
RU (1) RU2102988C1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1476541B1 (en) * 2002-01-18 2008-07-16 ZymoGenetics, Inc. Cytokine (zcytor17 ligand)

Also Published As

Publication number Publication date
RU2102988C1 (en) 1998-01-27

Similar Documents

Publication Publication Date Title
US5789384A (en) Pharmaceutical dipeptide compositions and methods of use thereof
AR002976A1 (en) PARENTERAL PHARMACEUTICAL FORMULATIONS OF LONG-TERM EFFECT OF INSULIN; CRYSTALS OF SUCH ANALOGUES APPLICABLE IN SUCH FORMULATIONS AND PROCEDURE OF THE FORMULATIONS MENTIONED
KR970706830A (en) COMPOSITION OF CISPLATIN IN COMBINATION WITH 2, 2'-DITHIO-BIS (ETHANESULFONATE) (DIMESNA)
GB2193631A (en) Stable granulocyte colony stimulating factor composition
RU94046251A (en) Glucagon-like peptide and derivatives of insulinotropine, method of synthesis, pharmaceutical compositions, method of diabetes treatment
JPH06507639A (en) Amino acid sequence homology between selectin and B pertussis toxin - peptides derived therefrom, antibodies thereto, pharmaceutical compositions
US6566334B1 (en) Short amphipathic peptides with activity against bacteria and intracellular pathogens
DK175381B1 (en) Pharmaceutical composition for the treatment of immunodeficiency conditions
JPS63146829A (en) Stable granulocyte colony stimulating factor-containing preparation
US4322341A (en) Peptide, process for preparation thereof and use thereof
JPH06507386A (en) therapeutic peptides
ES2223105T3 (en) PEPTIDE FRAGMENT OF THE ANTI-LPS FACTOR OF LIMULO (LALF) THAT HAS ANTIVIRICAL ACTION.
RU95101728A (en) Preparation exhibiting immunomodulating properties
US4349466A (en) Peptide, process for preparation thereof and use thereof
SV1996000001A (en) NEW LISOZYME DIMER APPLICATIONS
KR950005325A (en) Pharmaceutical composition
ES2292244T3 (en) USE OF LISOZYM C MODIFIED TO PREPARE MEDICINAL COMPOSITIONS TO TREAT CERTAIN SERIOUS DISEASES.
Kadurugamuwa et al. Protein antigens of encapsulated Klebsiella pneumoniae surface exposed after growth in the presence of subinhibitory concentrations of cephalosporins
EP0302836B1 (en) Pharmaceutical compositions for topical use containing miocamycin
US5268169A (en) Treatment method of ovarian cancer using interferon gamma
RU2349339C1 (en) Medicine with immune modifying, antivirus, antibacterial antioxidising, membrane stabilising, cartilage and connective tissue growth stimulating effect
JP2766303B2 (en) Superoxide dismutase modified with glycosaminoglycan and method for producing the same
KR100266929B1 (en) Pharmaceutical lysine-containing polypeptide compositions and methods of use thereof.
EP1031351B1 (en) Leishmaniasis remedy containing glucopyranose derivative as the active ingredient
US3773928A (en) Treatment of virus-induced diseases with orgotein